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Abstract
Objectives: Celiac disease (CD), a genetically predisposed intolerance for gluten, is associated with an increased risk of
major depressive disorder (MDD). We investigated whether dietary intake and serum levels of the essential n-3
polyunsaturated fatty acids (PUFA) eicosapentaenoic acid (EPA) and docosahexanoic acid (DHA) found in fatty fish play a
role in this association.
Methods: Cross-sectional study in 71 adult CD patients and 31 healthy volunteers, matched on age, gender and level of
education, who were not using n-3 PUFA supplements. Dietary intake, as assessed using a 203-item food frequency
questionnaire, and serum levels of EPA and DHA were compared in analyses of covariance, adjusting for potential
confounders. Serum PUFA were determined using gas chromatography.
Results: Mean serum DHA was significantly higher in CD patients (1.72 mass%) than controls (1.28 mass%) after
multivariable adjustment (mean diff. 0.45 mass%; 95% CI: 0.22–0.68; p= 0.001). The mean intake of EPA plus DHA did not
differ between CD patients and controls after multivariable adjustment (0.15 and 0.22 g/d, respectively; p= 0.10). There
were no significant differences in intake or serum levels of EPA and DHA between any of the CD patient groups (never
depressed, current MDD, minor/partially remitted MDD, remitted MDD) and controls.
Conclusions: Patients on a long term gluten-free diet had similar intakes of EPA plus DHA compared to controls. Contrary to
expectations, DHA serum levels were significantly higher in CD patients compared to healthy controls and were unrelated
to MDD status.
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Introduction
Celiac disease (CD) is a genetically predisposed intolerance for
gluten that affects approximately 1 in 160 people [1]. CD is caused
by an inappropriate enhanced immune response of the T-
lymphocytes of the small intestines to gluten peptides. This results
in intestinal malabsorption, atrophy of the intestinal villi and
chronic inflammation of the jejunal mucosa of the small intestine.
There is currently no cure for CD, but a gluten-free diet improves
the histopathology as well as symptoms like weight loss,
steatorrhea, diarrhea, abdominal distension, and pain [2]. Besides
these intestinal problems, CD is associated with an almost doubled
prevalence of major depressive disorder (MDD) [3–9]. Its
prevalence rate remains high when a gluten-free diet is initiated
[10,11], and may even increase after initiation of the gluten-free
diet [12–15].
Although the burden of having a chronic disease might be
sufficient to cause MDD in some patients nutrient deficiencies due
to malabsorption and the mandatory restrictive diet may also
contribute. Treated CD patients often obtain restoration of the
function and structure of their atrophied intestinal villi which
should correct their malabsorption problems [16], but the strict
gluten-free diet may induce nutrient deficiencies in itself. The
gluten-free diet has been found to be low in micronutrients and
fatty acids like iron, calcium, B vitamins, alpha-linolenic acid and
arachidonic acid [17–19], and CD patients may avoid high fat
meals (including fatty fish) that induces steatorrhea and other
intestinal problems. Eicosapentaenoic acid (EPA, 20:5n-3), doc-
osahexaenoic acid (DHA, 22:6n-3) and alpha-linolenic acid (ALA,
18:3n-3) are essential long-chain n-3 polyunsaturated fatty acids
(PUFA) that are important components of the human diet. EPA
and DHA are found in fatty fish, while ALA is found in green
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vegetables, nuts (e.g. walnuts), and vegetable oils (e.g. canola and
soybean oils). There is only a minor pathway of biosynthesis from
the precursor ALA to EPA and DHA with an approximately 10–
15% efficiency [20,21], and vegetarians and persons who do not
eat fish may depend on this metabolic pathway for their n-3
PUFA. EPA and DHA concentrations in plasma phospholipid
have been found to largely reflect dietary intakes of these fatty
acids. DHA comprises about 30% of the fatty tissue in the central
nervous system [22] and is a precursor to the signaling eicosanoid
molecules prostaglandins and leukotrines involved in the regula-
tion of inflammation and microvascular control. EPA and DHA
are considered to have anti-inflammatory effects in the human
body [23].
There is evidence that an increased dietary intake of DHA and
EPA, and possibly ALA, may lower the risk of MDD [24–26].
Also, circulating levels of n-3 PUFA (or their ratio to n-6
unsaturated fatty acids) have been inversely associated with MDD
[27,28] and depressive symptoms [29]. Randomized trials with n-3
PUFA supplementation studies have shown mixed results [30–34].
CD is associated with a higher prevalence of MDD [3–9].
Several studies have found that the daily intake of total fat is
significantly higher in CD patients. Furthermore, CD patients’
total energy intake is significantly lower than that of healthy
controls [35–37] but no previous study has analyzed the intake of
n-3 PUFA in CD patients or its relationship with MDD. Several
paediatric studies suggest that the lipid profile is different in CD
patients than in healthy controls, but most did not focus on n-3
[38–40]. A small paediatric study found no significant difference in
total serum n-3 fatty acids among 7 patients with active CD, 6
patients in remission and 11 controls, however arachidonic acid to
DHA ratio in patients in remission was significantly higher than in
controls [41]. In adults, DHA and EPA serum levels were
significantly lower than in controls at time of diagnosis and after
one year of gluten-free diet treatment [42].
In summary, n-3 fatty acid intake and blood levels seem to be
associated with MDD. Some studies suggest an association
between CD and circulating n-3 fatty acid levels, but studies are
small and mainly done in children. N-3 fatty acid intake has not
previously been measured in CD patients. Our aim was to
investigate whether dietary intake and serum levels of the essential
n-3 polyunsaturated fatty acids (PUFA) eicosapentaenoic acid
(EPA) and docosahexanoic acid (DHA), play a role in the
association between CD and depression. We hypothesized that
the gluten-free diet may cause low EPA and DHA intake and
serum levels, resulting in an increased risk of MDD in patients
with CD. Therefore, we compared intake and serum levels of EPA
and DHA among groups of CD patients with and without MDD,
and compared dietary intake of EPA and DHA in CD patients




A cohort of CD patients was recruited from the 2,265
participants (age 18–93 y) of a previous survey study [9] performed
among adult members of the Dutch Celiac Association (NCV), as
shown in a flow chart (Figure 1).
216 CD patients in the regions Leiden and Amsterdam were
contacted and screened for assignment to the never depressed,
remitted depressed and currently depressed CD patient study
conditions. Participants with self-reported depressive symptoms
were oversampled in order to obtain equal group sizes. Healthy,
never-depressed controls were recruited from the 1,295 partici-
pants of another study that aimed to gather reference data from
the general population (‘Normquest’ study) [43]. Eligible healthy
participants in the Leiden region (N= 615) were pre-screened for
mood disorders and were matched for age, gender and level of
education. Between October 2010 and April 2011, 85 CD patients
and 42 controls took part. Written confirmation of CD diagnosis
was requested from the treating specialists and was obtained for all
but 8 (11.2%) participants. Participants were excluded if they were
younger than 18, had ulcerative colitis, Crohn’s disease, current
chemotherapy or conditions which would make the testing session
unreliable or impossible such as severe psychosis, mental
retardation, blindness or deafness. CD participants were excluded
if they were on the gluten-free diet less than 2 years or had self-
reported low adherence to the gluten-free diet. Healthy controls
where excluded if they had celiac disease, shared a household or
had a 1st degree family relation with a CD patient or had any
mood disorder diagnosis on MINI-plus interview [43]. For the
current analyses the following subjects were excluded (Figure 1):
those with missing data on any main variables (n = 0), bipolar
disorder (n = 3), current alcohol abuse (n = 3), current drug abuse
(n = 1), not fasting on morning of testing (n = 1), healthy control
with lifetime diagnosis on repeated MINI-plus interview of any
mood disorder (n = 6), use of fatty acid (i.e., n-3 PUFA) food
supplements (n = 11).
Procedure
In accordance with the declaration of Helsinki, this study was
reviewed and approved by the Medical Ethics Committee of the
Leiden University Medical Centre and all participants provided
written informed consent before the start of data collection.
Participants had the capacity to consent, as assessed during
screening, and there was no surrogate consent procedure. The
interview and the blood collection was performed at the Leiden
University Medical Center or at a participating general practi-
tioners office in Amsterdam. Six participants were tested at home
due to their advanced age or disability. Participants were sent the
study information and instructions, the food frequency question-
naire, the Celiac Disease Adherence Test, a Lifestyle and Health
questionnaire, and an informed consent form two weeks before the
day of testing. Participants were fasting and refrained from
smoking in the hour prior to blood sampling. The testing day
started with the physical examination and blood collection, after
which participants consumed a light breakfast.
Instruments
Psychiatric diagnoses. The Dutch version [44] of the
complete Mini International Neuropsychiatric Interview Plus
5.0.0-R (MINI-Plus) was administered [45]. The MINI is a
structured clinical diagnostic interview of current and lifetime
Axis-I disorders according to the criteria of the Diagnostic and
Statistical Manual of Mental Disorders – Fourth Edition (DSM-
IV) [46]. A minimal modification was made to the criteria for
scoring ‘MDD partially in remission’, using the criteria suggested
by Rush et al. [47]. Participants who had never experienced a
mood disorder were placed in the ‘never’ group. Participants with
dysthymia were placed in the MDD groups (n = 1 in the current
MDD, and n= 2 remitted MDD group). Participants who were
currently suffering from an episode of MDD or dysthymia were
placed in the ‘current’ group. Participants who recently had an
episode of MDD or dysthymia but who now had subclinical
symptoms were placed in the ‘partially remitted’ group. Partici-
pants who had suffered from MDD, and currently experienced an
absence of both sad mood and reduced interest and no more than
three of the remaining seven symptoms of MDD for three or more
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weeks were placed in the ‘remitted’ group. All participants were
tested and interviewed by two interviewers (from five interviewers
in total). At the end of each session both raters tried to reach
agreement on all diagnoses. When agreement could not be
reached, an intervision meeting was scheduled with the full
research team during which consensus was reached.
Food frequency questionnaire. We used an updated
version of a validated semi-quantitative food frequency question-
naire that was previously used in epidemiological studies in the
Netherlands (45,47,48) The questionnaire covers the 1-month
intake of 203 food items and beverages. Information on use of food
supplements is also obtained. The questionnaire was sent to the
participants and filled in at home. A data check for completeness
was performed during the visit to the study center. The food
frequency questionnaire was not designed to take the gluten-free
diet into account, and therefore additional questions on the
ingredients of the gluten-free food products were included. Also,
we asked participants to provide the packaging and labels of the
gluten-free products that they had used in the past month.
Nutrient intake was calculated using the Dutch Food Composition
Table (‘Nederlands Voedingsstoffenbestand’; NEVO, 2006),
which was extended for gluten free products by a dietician [48].
Other variables. Body weight (kg) and height (cm) were
measured and body mass index (kg/m2) was computed. Blood
pressure was measured twice after a 5-minute rest, once lying
down before breakfast and once sitting up after having breakfast.
Physical activity was assessed using the Physical Activity Scale for
the Elderly (PASE) [49], to estimate ‘metabolic equivalents of task’
(MET) minutes. Smoking behavior, alcohol consumption, and self-
reported medication use was assessed using questionnaires.
Furthermore the nature and method of CD diagnosis were
assessed, as well as current and lifetime medical disorders.
Blood sampling and other measures. Fasting venous
blood samples were obtained on ice, centrifuged and serum was
kept at 280uC within 3 hours after collection. The fatty acids
(omega-3, omega-6 and omega-6:omega-3 ratio) from total lipids
and high-sensitivity C-reactive protein (hsCRP) were assessed.
hsCRP concentrations (mg/L) were measured using nephelome-
try. Fasting serum fatty acids were determined as percentage of
total fatty acids by a slightly modified gas chromatographic
procedure as described by Lepage and Roy [50]. To 100 mL of
serum 15 mL of a 1.0 mg/ml solution of heptadecanoic acid in
chloroform/methanol (1:1; v/v) was added as an internal standard
and subsequently 2.0 ml of methanol/benzene (4:1; v/v). Then
200 mL of acetylchloride was added slowly and derivatization was
performed for 1 h at 100uC. After adding 5 ml of a 6% (w/v)
potassium carbonate solution in water and cooling of the mixture
it was centrifuged and as much as possible of the benzene upper
layer was isolated. This was dried under a gentle nitrogen flow and
the residue was taken up in 50 mL of hexane. Finally 1 mL of this
sample was injected using split-injection (1:20) on a Trace/Focus
gaschromatograph (Interscience, Breda, The Netherlands) using a
30 m capillary BPX-70 column (SGE, Ringwood, Australia) and
fatty acids were quantified by calculating the peak area ratios of
the fatty acids and the internal standard.
Assessment of adherence to gluten-free diet and CD
diagnosis. The current level of adherence to the gluten-free diet
was assessed with a single self-report question [9] as well as with
the Celiac Disease Adherence Test (CDAT) [51]. In addition a
series of questions was asked to assess diet history (duration, age at
onset, and any diet interruptions).
Statistical Analysis
Group differences were analyzed using chi-squared (x2) tests for
categorical variables and analysis of variance (ANOVA) for
continuous variables. Analysis of covariance (ANCOVA) was used
to adjust for age, gender, level of education, BMI, smoking,
alcohol use and statin use in model 1. To assess the potential
mediation by differences in dietary intake, we additionally adjusted
for daily intake of EPA and DHA when analyzing serum levels of
n-3 PUFA in model 2. Odds ratios were calculated using logistic
regression analysis assessing the risk of MDD according to EPA
and DHA intake and serum EPA and DHA levels. Statistical
significance was inferred at a two-sided p,0.05. Analyses were
done with SPSS software (Version 19.0. Armonk, NY: IBM Corp).
Figure 1. Flow chart of participants in the study.
doi:10.1371/journal.pone.0097778.g001
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Results
Participant Characteristics
No participant had missing data on the main study variables.
Patients with CD were on average 54 years old (range 20–86 years)
and 76% was female (Table 1). Healthy controls were on average
51 years old (range 22–66 years), 65% was female. Both groups
had an above average education level. The CD group (n= 71)
comprised 46 participants (65%) who had one or more (up to 4)
current psychiatric diagnoses, mainly anxiety disorders. CD
patients were engaged in physical activity 60 MET hours per
month less than healthy controls (p=0.03). On average, CD
patients were maintaining a gluten-free diet for an uninterrupted
period of 15.1 years (SD=11.5), ranging between 2.6 and 52
years. Length of current gluten-free diet did not differ significantly
among the 4 depression groups of CD patients. Self-reported diet
adherence in our sample could be categorized as ‘very strict’ in
74% of participants, ‘strict’ in 24%, and only 1% for ‘moderately
well’ to ‘poor’. Diet adherence according to Celiac Disease
Adherence Test results was categorized as ‘excellent’ or ‘very
good’ in 63% of participants, ‘very good’ to ‘fair’ in 26% and ‘fair’
to ‘poor’ in 11%.
Dietary Intake of Fat and Fatty Acids
Nutrient value tables specifically for the gluten-free diet were
used, which did not affect the estimations of EPA plus DHA
intake. Table 2 shows a no significant difference in overall intake
of fat and fatty acids nor were there significant differences after
controlling for covariates. The intake of EPA plus DHA was not
significantly different in CD patients compared to controls (mean
0.17 and 0.21 g/d, respectively; F(1,100) = 1.06; p=0.31) nor after
controlling for covariates (mean 0.15 and 0.22 g/d, respectively;
mean diff. 0.073 g/d; 95% CI: 20.015–0.161; p=0.10). The
MDD groups did not differ from controls on this variable either.
The intakes of total energy, total fat, unsaturated fatty acids, ALA
and of EPA plus DHA did not differ significantly between CD
patients and controls, nor between the CD depression groups and
controls. After controlling for confounders, energy intake seemed
to differ among groups, but when comparing the CD patient
group as a whole to controls this difference was not significant
(p=0.67).
Serum Levels of Fatty Acids
The n-6: n-3 ratio was approximately 17:1 in both groups with
no significant difference between CD patients and controls after
controlling for confounders. Intake of EPA plus DHA showed a
small but significant Pearson correlation to serum EPA as well as
to serum DHA concentrations in our total sample (n = 102;
r = 0.18, p=0.08 and r = 0.27, p=0.007, respectively). This
indicates that fatty fish intake was indeed associated with serum
DHA, more so than with serum EPA concentrations, but that it
could only explain a small part of its variance. None of the tested
serum PUFA levels differed significantly between CD patients
(n = 71) and healthy controls (n = 31), except for DHA (table 3).
DHA serum level in CD patients was significantly different from
controls (mean 1.72 and 1.28 mass%, respectively;
F(1,100) = 15,47; p=0.001). After controlling for confounders the
mean level of DHA in CD patients was on average 1.72 mass%
Table 1. Socio-demographic and medical characteristics in celiac disease patients and matched controls.
Controls (n=31) Celiac disease (n =71) P-value*
Age (years) 51.1613.3 53.9618.7 0.45
Gender
- Male 11 (35%) 17 (24%) 0.23
- Female 20 (65%) 54 (76%)
Level of education
- Low 7 (22.6%) 18 (25.4%) 0.52
- Intermediate 6 (19.4%) 20 (28.2%)
- High 18 (58.1%) 33 (46.5%)
Body mass index (kg/m2) 24.963.7 24.664.0 0.72
Blood pressure
- Systolic (mmHg) 120.5620.3 125.7621.6 0.25
- Diastolic (mmHg) 72.6610.5 69.2610.8 0.14
Statin use 6 (19.4%) 7 (9.9%) 0.19
Current smoker 7 (22.6%) 7 (9.9%) 0.09
Alcohol intake
- No 10 (32.3%) 31 (43.7%) 0.28
- 1–2 glasses/d 14 (45.2%) 32 (45.1%)
- $2 glasses/d 7 (22.6%) 8 (11.3%)
Number comorbid diseases 1.0 (0.0–2.0) 2.0 (1.0–3.0) 0.02
hsCRP (mg/L) 0.94 (0.50–2.31) 0.95 (0.31–2.13) 0.11
Physical activity (MET hours/week) 44.5635.1 30.6625.1 0.03
Data are presented as n (%), mean (6 SD) or median (Q1–Q3), when appropriate. ALA denotes alpha-linolenic acid; DHA, docosahexaenoic acid; EPA, Eicosapentaenoic
acid; hsCRP, High-sensitivity C-reactive protein; MET, metabolic equivalents of task.
*P-values by chi-squared test for categorical variables and by ANOVA for continuous variables.
doi:10.1371/journal.pone.0097778.t001
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versus 1.28 mass% for controls (mean diff. 0.45 mass%; 95% CI:
0.22–0.68 p,0.001). This difference remained significant after
controlling for dietary intake of EPA and DHA as an additional
covariate (mean diff. 0.39 mass%; 95% CI: 0.17–0.62 p,0.001),
where intake of EPA and DHA contributed significantly to the
regression model and explained 8% of the variance and group
membership explained 12% of the variance.
In post-hoc tests, we compared the mean serum levels of DHA
between the 4 CD groups using ANCOVA adjusting for
covariates. We did not find a significant difference in serum levels
among CD depression categories (figure 2). When comparing CD
patients with current and partially remitted MDD (cases) versus
CD patients with no or remitted MDD (controls), continuous EPA
levels were not associated with a higher risk of MDD with an odds
ratio of 0.90 (95% CI: 0.44–1.85; p=0.77) nor were DHA levels
with an odds ratio of 1.33 (95% CI: 0.58–3.08; p=0.50).
To take the influence of possible current inflammation into
account we performed a sensitivity analysis where we additionally
adjusted our multivariate model for log-transformed hsCRP levels,
which did not alter the results for serum EPA and DHA levels
(data not shown). In another sensitivity analysis, we excluded the 6
CD participants for whom the potential confirmed CD diagnosis
could not be retrieved. Again this did not alter our results for
serum EPA and DHA levels (data not shown). We investigated the
relationship between gluten-free diet characteristics and DHA
serum levels and DHA intake. Adherence to the gluten-free diet as
measured by the Celiac Disease Adherence Test did not predict
DHA serum levels (p=0.27), nor DHA intake (p=0.72). Length of
gluten-free diet did not predict DHA serum levels (p=0.77) or
DHA intake (p=0.70).
Discussion
Our study showed that treated CD patients had a higher serum
DHA level than healthy controls. This does not seem to reflect an
increased intake of EPA and DHA by CD patients on a gluten-free
Table 2. Daily dietary intakes in 31 controls and 71 patients with celiac disease with and without depression.
Controls Patients with celiac disease P-value*







Total energy (kcal/d) 1979698 20256102 17986153 18726149 18156165 0.64
Total fat (g/d) 72.964.7 73.265.1 66.566.2 76.567.2 70.767.9 0.89
Unsaturated fatty acids (g/d) 14.061.8 16.362.0 12.561.3 15.562.1 14.362.0 0.61
ALA (g/d) 1.0360.08 1.2360.16 1.0960.12 1.0860.11 1.0560.15 0.78
EPA plus DHA (g/d) 0.1760.03 0.2060.03 0.1560.03 0.3260.08 0.2060.08 0.18
Data are presented as mean (6 SE), when appropriate. ALA denotes alpha-linolenic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; MDD, major
depressive disorder.
*P-values by ANOVA for continuous variables; adjusted for gender, age, education, BMI, smoking, alcohol use, and statin use.
doi:10.1371/journal.pone.0097778.t002
Table 3. Serum fatty acid content in 31 controls and 71 patients with celiac disease with and without depression.
Controls Patients with celiac disease P-value*




(n=13) Current MDD (n=10)
Total fatty acids 10.0162.06 9.4762.14 9.8661.52 9.8661.76 10.2762.56 .62
C12:0 (Lauric A) 0.1560.01 0.1360.01 0.1560.02 0.1060.01 0.1260.02 .16
C14:0 (Myrisitic A) 1.2660.06 1.1960.06 1.2260.11 0.9760.08 1.2160.16 .45
C16:0 (Palmitic A) 25.0660.34 24.3460.25 24.5460.60 24.2060.38 24.2460.77 .48
C16:1. n-7 (Palmitoleic A) 2.4160.12 2.4760.16 2.1760.14 1.9960.16 2.1360.31 .25
C18:0 (Stearic A) 6.6760.11 6.7660.12 6.7160.21 6.5160.23 6.8860.29 .78
C18:1. n-9 (Oleic A) 20.9560.50 21.3060.44 20.6360.73 20.7360.70 22.0060.89 .71
C18:2. n-6 (LA) 28.6560.79 27.7160.80 28.7961.11 29.9961.04 28.3561.99 .66
C18:3. n-3 (ALA) 0.5660.03 0.6160.05 0.4860.03 0.5760.06 0.5360.06 .35
C20:4. n-6 (AA) 5.8960.21 6.3660.21 5.9160.34 5.6960.35 5.6760.42 .34
C20:5. n-3 (EPA) 0.7260.05 0.9260.12 0.9460.18 0.9460.25 0.7960.17 .65
C22:5. n-3 (DPA) 0.3560.02 0.4060.02 0.3660.03 0.3460.04 0.3660.03 .22
C22:6. n-3 (DHA) 1.2860.06 1.6560.09{ 1.7860.16{ 1.8760.20{ 1.6960.18{ .003**
Data are (adjusted) mean 6 standard errors (SE), total fatty acids in mmol/L, individual fatty acids as a % of total fatty acids. MDD denotes major depressive disorder.
{significantly different in post-hoc tests versus the controls.
*P-values by ANOVA for continuous variables; adjusted for gender, age, education, BMI, smoking, alcohol use, and statin use.
**additionally adjusted for daily intake of EPA and DHA.
doi:10.1371/journal.pone.0097778.t003
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diet, as fish fatty acid intake did not differ significantly among
these groups. We found no association between dietary intake or
serum levels of EPA or DHA and MDD status within the group of
CD patients, and therefore the differences in DHA levels could not
explain the differences in occurrence of MDD.
There is evidence that an increased dietary intake of DHA and
EPA, and possibly ALA, may lower the risk of MDD [24–26].
Also, circulating levels of n-3 PUFA (or their ratio to n-6
unsaturated fatty acids) have been inversely associated with MDD
[27,28] and depressive symptoms [29]. Randomized trials with n-3
PUFA supplementation studies have shown mixed results [30–34].
Some reviews have found lower EPA and DHA plasma levels in
depressed patients [30] and a small but significant benefit of EPA
and DHA supplementation in MDD patients [31]. Other reviews
found no effect of EPA and DHA supplementation on MDD [32]
and no beneficial effect of EPA and DHA supplementation on
mood in women with perinatal depressive symptoms [33] or
subjects not suffering from current MDD [34].
We found increased serum DHA in our CD patients, but no
difference in serum EPA, compared to controls which is
inconsistent with the literature. Although the literature on n-3
fatty acid metabolism in patients with CD, or chronic diseases in
general, is very limited, data suggest that severe malabsorption and
chronic gastrointestinal disorder is associated with essential fatty
acid deficiencies; in particular linoleic acid and DHA [52,53].
Some studies even propose permanent changes in fatty acid
metabolism [52–55]. Studies on n-3 fatty acid plasma levels and
fatty acid profiles in CD patients have shown mixed results, in
particular between studies done in paediatric [38,39,41] and adult
samples [42,56]. All studies however show unfavorable differences
in CD patients’ fatty acid profiles when comparing them to healthy
groups. For example, a study assessing recently diagnosed adult
CD patients found that patients’ DHA, EPA and arachidonic acid
serum levels increased after a one-year strict gluten-free diet but
stayed significantly lower than those of controls. Serum arachi-
donic acid and DHA levels improved most. As the authors propose
in their discussion, essential fatty acid concentration may continue
to increase after following a gluten-free diet for a longer period of
time. [42]. Studies into CD or the gluten-free diet are difficult to
compare however since differences in stages of disease activity of
CD, different length of the gluten-free diet and level of adherence
to the gluten-free diet need to be taken into account. For example,
paediatric patients with active CD had significant signs of essential
fatty acid deficiency, but when these patients were in remission
and on a gluten-free diet for one year or longer, their DHA levels
were not significantly lower than those of controls [41]. In
contrast, in our study in CD patients on a long term gluten-free
diet (mean 15 years) serum DHA levels were significantly higher
than healthy controls. As some authors have previously suggested
permanent changes in fatty acid metabolism in chronically ill
samples [52–55], we speculate that such a change may have
occurred in our sample of CD patients in remission. Possibly
through sustained activation of counterbalancing (e.g. anti-
inflammatory) processes that help to restore homeostasis, which
might have involved the formation of DHA [57–60]. After antigen
exposure is eliminated, chronic inflammation might slowly be
reduced by anti-inflammatory mechanisms including the increased
production of DHA. We hypothesize that the prolonged activation
of this process might have resulted in a permanent up-regulation of
DHA formation.
An alternative explanation is a change in PUFA intake due to
the exclusive nature of the gluten-free diet. Our questionnaire data
did however not reveal a significantly different dietary intake of
PUFA or total fat between patients and controls. It is therefore less
likely that our finding of an elevated DHA serum level is
attributable to differences in DHA intake as a result of the gluten-
free diet. We also found that using nutrient tables designed for the
gluten-free diet did not really alter the outcome of the FFQ on
variables involving fatty acids. This leads us to conclude that the
gluten-free diet does not really have an impact on main dietary
sources of fatty acids. Contrary to our findings most previous
studies found an increased intake of total fat in treated CD patients
[61–63]. But one study found equal fat intake when comparing
female participants only [64]. The lack of difference in energy
intake between treated CD patients and healthy controls we found
in our study is in line with earlier findings [36,61,62,64]. Some
other studies however found a significantly lower intake of energy
[65] or higher intake of energy [63,64]. Our findings point to a
normalization of fat and energy intake in CD patients who have
been living with the gluten-free diet for a long time. Whether this
Figure 2. Mean standard scores (with error bars representing standard errors) for plasma levels of doxosahexaenoic acid (DHA)
and eicosapentaenoic acid (EPA) in % of total fatty acids. The size of each square is proportional to the number of participants. Mean scores
are adjusted for gender, age, education, BMI, smoking, alcohol use, statin use, and daily intake of EPA and DHA. P-values by analysis of covariance.
doi:10.1371/journal.pone.0097778.g002
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finding is generalizable to samples from other populations remains
to be seen.
EPA and DHA supplementation in chronic inflammatory
diseases such as rheumatoid arthritis, Crohn’s disease and multiple
sclerosis may have beneficial effects on disease activity [66], but it
is unclear whether this also applies to CD. Because serum EPA
and DHA in our CD patients with depressive symptoms were
similar to levels in non-depressed CD patients, we consider a
beneficial effect of supplemental n-3 PUFA intake less likely.
However, well-designed randomized trials in CD patients with
MDD are warranted to definitely refute this hypothesis.
There are some limitations that need to be addressed. First, our
sample was relatively small. Second, as we did not include patients
with high dietary gluten exposure, our findings cannot be
extrapolated to CD patients not on a gluten-free diet or with
poor gluten-free diet adherence. However, previous research did
not show a relationship between level of diet adherence and
psychopathology [9,67] nor is a relation likely between very small
dietary transgressions and medical symptoms [68]. Third, both
interviewers and participants were aware of the purpose of the
study giving room to bias in the assessment of MDD. This possible
bias was addressed to some extent by having every diagnostic
interview observed by a second rater and discussed in intervision.
Clinical Implications and Future Research
DHA serum levels were significantly higher in CD patients on a
long term strict gluten-free diet and presumed in remission than in
healthy controls, which may reflect alterations in fatty acid
metabolism in response to the prolonged period of intestinal
inflammation. Within the group of CD patients, we found no
association between dietary or serum EPA plus DHA and
depression status. Therefore, our findings do not support the
hypothesis that supplementation of n-3 PUFA in CD patients after
the first years of gluten-free diet is warranted to reduce the risk of
MDD. Nevertheless, our findings warrant confirmation by other
studies, preferably randomized controlled trials.
Acknowledgments
We gratefully acknowledge Els Siebelink, Susanne Tielemans and Eveline
Waterham for their invaluable help in calculating the FFQ gluten-free
nutrient tables, as well as Dr. W. Onkenhout for the analysis of the fatty
acids. We also acknowledge the contribution of all students who were
involved in this project.
Author Contributions
Conceived and designed the experiments: NVH. Performed the experi-
ments: NVH NJ. Analyzed the data: NVH EG NJ. Contributed reagents/
materials/analysis tools: JG. Wrote the paper: NVH EG JG NJ WVDD.
References
1. Biagi F, Biagi C, Klersy D, Balduzzi G, Corazza (2010) Are we not over-
estimating the prevalence of coeliac disease in the general population? Annals of
medicine (Helsinki) 42: 557–561.
2. Rubio-Tapia A, Rahim MW, See JA, Lahr BD, Wu T-T, et al. (2010) Mucosal
Recovery and Mortality in Adults With Celiac Disease After Treatment With a
Gluten-Free Diet. Am J Gastroenterol 105: 1412–1420.
3. Addolorato G, Leggio L, D’Angelo C, Mirijello A, Ferrulli A, et al. (2008)
Affective and psychiatric disorders in celiac disease. Dig Dis 26: 140–148.
4. Addolorato G, Stefanini GF, Capristo E, Caputo F, Gasbarrini A, et al. (1996)
Anxiety and depression in adult untreated celiac subjects and in patients affected
by inflammatory bowel disease: A personality ‘‘trait’’ or a reactive illness?
Hepato-Gastroenterology 43: 1513–1517.
5. Carta MG, Hardoy MC, Boi MF, Mariotti S, Carpiniello B, et al. (2002)
Association between panic disorder, major depressive disorder and celiac
disease: a possible role of thyroid autoimmunity. J Psychosom Res 53: 789–793.
6. Ciacci C, Iavarone A, Mazzacca G, De Rosa A (1998) Depressive symptoms in
adult coeliac disease. Scand J Gastroenterol 33: 247–250.
7. Hernanz A, Polanco I (1991) Plasma precursor amino acids of central nervous
system monoamines in children with coeliac disease. Gut 32: 1478–1481.
8. Rostom A, Murray JA, Kagnoff MF (2006) American Gastroenterological
Association (AGA) Institute Technical Review on the Diagnosis and Manage-
ment of Celiac Disease. Gastroenterology 131: 1981–2002.
9. van Hees NJM, Van der Does W, Giltay EJ (2013) Coeliac disease, diet
adherence and depressive symptoms. J Psychosom Res 74: 155–160.
10. Addolorato G, Mirijello A, D’Angelo C, Leggio L, Ferrulli A, et al. (2008) State
and trait anxiety and depression in patients affected by gastrointestinal diseases:
psychometric evaluation of 1641 patients referred to an internal medicine
outpatient setting. International journal of clinical practice 62: 1063–1069.
11. Karwautz A, Wagner G, Berger G, Sinnreich U, Grylli V, et al. (2008) Eating
pathology in adolescents with celiac disease. Psychosomatics 49: 399–406.
12. Hallert C, Gotthard R, Jansson G, Norrby K, Walan A (1983) Similar
prevalence of coeliac disease in children and middle-aged adults in a district of
Sweden. Gut 24: 389–391.
13. Corvaglia L, Catamo R, Pepe G, Lazzari R, Corvaglia E (1999) Depression in
adult untreated celiac subjects: diagnosis by the pediatrician. Am J Gastroenterol
94: 839–843.
14. Addolorato G, Capristo E, Ghittoni G, Valeri C, Masciana R, et al. (2001)
Anxiety but not depression decreases in coeliac patients after one-year gluten-
free diet: A longitudinal study. Scandinavian journal of gastroenterology 36:
502–506.
15. Pynnonen P, Isometsa E, Verkasalo M, Savilahti E, Aalberg V (2002) Untreated
celiac disease and development of mental disorders in children and adolescents.
Psychosomatics 43: 331–334.
16. Abenavoli L, Proietti I, Leggio L, Ferrulli A, Vonghia L, et al. (2006) Cutaneous
manifestations in celiac disease. World Journal of Gastroenterology 12: 843–852.
17. Thompson T, Dennis M, Higgins LA, Lee AR, Sharrett MK (2005) Gluten-free
diet survey: are Americans with coeliac disease consuming recommended
amounts of fibre, iron, calcium and grain foods? Journal of Human Nutrition
and Dietetics 18: 163–169.
18. Alvarez-Jubete L, Arendt EK, Gallagher E (2009) Nutritive value and chemical
composition of pseudocereals as gluten-free ingredients. International Journal of
Food Sciences and Nutrition 60: 240–257.
19. Thompson T (2000) Folate, iron, and dietary fiber contents of the gluten-free
diet. J Am Diet Assoc 100: 1389–1396.
20. Emken EA, Rohwedder WK, Adlof RO, Rakoff H, Gulley RM (1987)
Metabolism in humans of cis-12, trans-15-octadecadienoic acid relative to
palmitic, stearic, oleic and linoleic acids. Lipids 22: 495–504.
21. Emken EA, Adlof RO, Gulley RM (1994) Dietary linoleic acid influences
desaturation and acylation of deuterium-labeled linoleic and linolenic acids in
young adult males. Biochimica et biophysica acta 1213: 277–288.
22. Innis SM (2000) The role of dietary n-6 and n-3 fatty acids in the developing
brain. Developmental neuroscience 22: 474–480.
23. Holub BJ (2002) Clinical nutrition: 4. Omega-3 fatty acids in cardiovascular
care. CMAJ: Canadian Medical Association journal = journal de l’Association
medicale canadienne 166: 608–615.
24. DeMar JC Jr, Ma K, Bell JM, Igarashi M, Greenstein D, et al. (2006) One
generation of n-3 polyunsaturated fatty acid deprivation increases depression
and aggression test scores in rats. J Lipid Res 47: 172–180.
25. Freeman MP (2000) Omega-3 fatty acids in psychiatry: a review. Annals of
clinical psychiatry: official journal of the American Academy of Clinical
Psychiatrists 12: 159–165.
26. Lesperance F, Frasure-Smith N, St-Andre E, Turecki G, Lesperance P, et al.
(2011) The efficacy of omega-3 supplementation for major depression: a
randomized controlled trial. J Clin Psychiatry 72: 1054–1062.
27. Maes M, Smith R, Christophe A, Cosyns P, Desnyder R, et al. (1996) Fatty acid
composition in major depression: decreased omega 3 fractions in cholesteryl
esters and increased C20: 4 omega 6/C20: 5 omega 3 ratio in cholesteryl esters
and phospholipids. Journal of affective disorders 38: 35–46.
28. Peet M, Horrobin DF (2002) A dose-ranging study of the effects of ethyl-
eicosapentaenoate in patients with ongoing depression despite apparently
adequate treatment with standard drugs. Arch Gen Psychiatry 59: 913–919.
29. Tiemeier H, van Tuijl HR, Hofman A, Kiliaan AJ, Breteler MM (2003) Plasma
fatty acid composition and depression are associated in the elderly: the
Rotterdam Study. Am J Clin Nutr 78: 40–46.
30. Lin PY, Huang SY, Su KP (2010) A meta-analytic review of polyunsaturated
fatty acid compositions in patients with depression. Biological psychiatry 68:
140–147.
31. Appleton KM, Rogers PJ, Ness AR (2010) Updated systematic review and meta-
analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed
mood. Am J Clin Nutr 91: 757–770.
32. Bloch MH, Hannestad J (2012) Omega-3 fatty acids for the treatment of
depression: systematic review and meta-analysis. Molecular psychiatry 17: 1272–
1282.
Celiac Disease, Omega-3 and Depression
PLOS ONE | www.plosone.org 7 May 2014 | Volume 9 | Issue 5 | e97778
33. Jans LA, Giltay EJ, Van der Does AJ (2010) The efficacy of n-3 fatty acids DHA
and EPA (fish oil) for perinatal depression. The British journal of nutrition 104:
1577–1585.
34. Giltay EJ, Geleijnse JM, Kromhout D (2011) Effects of n-3 fatty acids on
depressive symptoms and dispositional optimism after myocardial infarction.
Am J Clin Nutr 94: 1442–1450.
35. Ferrara P, Cicala M, Tiberi E, Spadaccio C, Marcella L, et al. (2009) High fat
consumption in children with celiac disease. Acta Gastroenterol Belg 72: 296–
300.
36. Hallert C, Grant C, Grehn S, Granno C, Hulten S, et al. (2002) Evidence of
poor vitamin status in coeliac patients on a gluten-free diet for 10 years. Aliment
Pharmacol Ther 16: 1333–1339.
37. Mariani P, Viti MG, Montouri M, La Vecchia A, Cipolletta E, et al. (1998) The
Gluten-Free Diet: A Nutritional Risk Factor for Adolescents with Celiac
Disease? Journal of Pediatric Gastroenterology and Nutrition 27: 519–523.
38. Rey J, Frezal J, Polonovski J, Lamy M (1965) [Modifications of plasma lipids in
disorders of intestinal absorption in children]. Rev Fr Etud Clin Biol 10: 488–
494.
39. Jaskiewicz J, Szafran H, Kruszewska M, Brylska U, Krol M (1987) The effect of
gluten-free diet supplemented with Humana-MCT on the level of lipid fractions
in blood serum of infants with coeliac disease. Acta Physiol Pol 38: 22–30.
40. Rosenthal E, Hoffman R, Aviram M, Benderly A, Erde P, et al. (1990) Serum
lipoprotein profile in children with celiac disease. J Pediatr Gastroenterol Nutr
11: 58–62.
41. Steel DM, Ryd W, Ascher H, Strandvik B (2006) Abnormal fatty acid pattern in
intestinal mucosa of children with celiac disease is not reflected in serum
phospholipids. J Pediatr Gastroenterol Nutr 43: 318–323.
42. Solakivi T, Kaukinen K, Kunnas T, Lehtimaki T, Maki M, et al. (2009) Serum
fatty acid profile in celiac disease patients before and after a gluten-free diet.
Scand J Gastroenterol 44: 826–830.
43. Schulte-van Maaren YW, Carlier IV, Giltay EJ, van Noorden MS, de Waal
MW, et al. (2013) Reference values for mental health assessment instruments:
objectives and methods of the Leiden Routine Outcome Monitoring Study.
Journal of evaluation in clinical practice 19: 342–350.
44. van Vliet IM (2007) The MINI-International Neuropsychiatric Interview. A
brief structured diagnostic psychiatric interview for DSM-IV en ICD-10
psychiatric disorders. Tijdschrift voor psychiatrie 49: 393–397.
45. Sheehan DV (1998) The Mini-International Neuropsychiatric Interview
(M.I.N.I.): the development and validation of a structured diagnostic psychiatric
interview for DSM-IV and ICD-10. The Journal of clinical psychiatry 59 Suppl
20: 22–33; quiz 34–57.
46. American Psychiatric Association APATFoDSMIV (2000) Diagnostic and
statistical manual of mental disorders: DSM-IV-TR. Washington, DC:
American Psychiatric Association.
47. Rush AJ, Kraemer HC, Sackeim HA, Fava M, Trivedi MH, et al. (2006) Report
by the ACNP Task Force on response and remission in major depressive
disorder. Neuropsychopharmacology: official publication of the American
College of Neuropsychopharmacology 31: 1841–1853.
48. Stichting Nederlands Voedingsstoffenbestand (NEVO foundation). Dutch Food
Composition Table 2006. The Netherlands Nutrition Centre, The Hague, The
Netherlands.
49. Washburn RA, Smith KW, Jette AM, Janney CA (1993) The Physical Activity
Scale for the Elderly (PASE): development and evaluation. J Clin Epidemiol 46:
153–162.
50. Lepage G, Roy CC (1986) Direct transesterification of all classes of lipids in a
one-step reaction. Journal of lipid research 27: 114–120.
51. Leffler DA, Dennis M, Edwards George JB, Jamma S, Magge S, et al. (2009) A
simple validated gluten-free diet adherence survey for adults with celiac disease.
Clinical gastroenterology and hepatology: the official clinical practice journal of
the American Gastroenterological Association 7: 530–536, 536 e531–532.
52. Siguel EN, Lerman RH (1996) Prevalence of essential fatty acid deficiency in
patients with chronic gastrointestinal disorders. Metabolism: clinical and
experimental 45: 12–23.
53. Chambrier C, Garcia I, Bannier E, Gerard-Boncompain M, Bouletreau P (2002)
Specific changes in n-6 fatty acid metabolism in patients with chronic intestinal
failure. Clinical nutrition 21: 67–72.
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